Bionicsgene Signs Agreement with CRO to Begin Clinical Trial for Immuno-Oncology Treatment in China
Bionicsgene Signs Agreement with CRO to Begin Clinical Trial for Immuno-Oncology Treatment in China
Seoul, Korea, July 02, 2018 – Bionicsgene, which is to be invested by KCLAVIS Bio-global Syndicate, announced the launching of a clinical trial for immuno-oncology treatment with C&R Research, an Asia-based CRO. Through the contract, the companies will run the phase 1 trial for the immuno-oncology treatment PVX-024 owned by OncoPep, of which Bionicsgene is the major shareholder.
C&R Research is the most renowned CRO in Korea, has established expertise in clinical trials for biopharmaceuticals and medical devices through 20 years of experience and more than 1200 clinical studies and licensing. Also, the company was the first Korean CRO to expand to China, having established a joint venture C&R-Lewei JV in collaboration with Beijing Lewei Bio & Tech. Co., Ltd in 2010.
A Bionicsgene official explained, “The PVX-024, which shows exceptionally high immune reaction
in the Asian population, has completed the pre-clinical phase at the Dana-Farber Cancer Institute in the U.S. Through this contract, C&R Research will not only prepare for new drug approval but also manage site selection in China and Korea, and it will conduct market research of leading immuno-oncology vaccines and indications, etc.”
